Literature DB >> 31675459

Design and Analysis of the 4-Anilinoquin(az)oline Kinase Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure-Activity Relationships.

Christopher R M Asquith1,2, Tuomo Laitinen3, James M Bennett4, Carrow I Wells2, Jonathan M Elkins4,5, William J Zuercher2,6, Graham J Tizzard7, Antti Poso3,8.   

Abstract

The 4-anilinoquinoline and 4-anilinoquinazoline ring systems have been the focus of significant efforts in prior kinase drug discovery programs, which have led to approved medicines. Broad kinome profiles of these compounds have now been assessed with the advent of advanced screening technologies. These ring systems, while originally designed for specific targets including epidermal growth factor receptor (EGFR), but actually display a number of potent collateral kinase targets, some of which have been associated with negative clinical outcomes. We have designed and synthesized a series of 4-anilinoquin(az)olines in order to better understand the structure-activity relationships of three main collateral kinase targets of quin(az)oline-based kinase inhibitors: cyclin G associated kinase (GAK), STE20-like serine/threonine-protein kinase (SLK) and serine/threonine-protein kinase 10 (STK10). This was achieved through a series of quantitative structure-activity relationship (QSAR) analysis, water mapping of the kinase ATP binding sites and extensive small-molecule X-ray structural analysis.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  4-anilinoquinazoline; 4-anilinoquinoline; Water Network; cyclin G associated kinase; quantitative structure-activity relationships

Year:  2019        PMID: 31675459     DOI: 10.1002/cmdc.201900521

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  5 in total

1.  Identification of 4-Anilinoquin(az)oline as a Cell-Active Protein Kinase Novel 3 (PKN3) Inhibitor Chemotype.

Authors:  Christopher R M Asquith; Louisa Temme; Michael P East; Tuomo Laitinen; Julie Pickett; Frank E Kwarcinski; Parvathi Sinha; Carrow I Wells; Gary L Johnson; Reena Zutshi; David H Drewry
Journal:  ChemMedChem       Date:  2022-05-09       Impact factor: 3.540

2.  Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors.

Authors:  Pei-Tzu Huang; Sirle Saul; Shirit Einav; Christopher R M Asquith
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

3.  Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies.

Authors:  Marwah Karim; Sirle Saul; Luca Ghita; Malaya Kumar Sahoo; Chengjin Ye; Nishank Bhalla; Chieh-Wen Lo; Jing Jin; Jun-Gyu Park; Belén Martinez-Gualda; Michael Patrick East; Gary L Johnson; Benjamin A Pinsky; Luis Martinez-Sobrido; Christopher R M Asquith; Aarthi Narayanan; Steven De Jonghe; Shirit Einav
Journal:  Antiviral Res       Date:  2022-06-20       Impact factor: 10.103

4.  The cyclin G-associated kinase (GAK) inhibitor SGC-GAK-1 inhibits neurite outgrowth and synapse formation.

Authors:  Jun Egawa; Reza K Arta; Vance P Lemmon; Melissa Muños-Barrero; Yan Shi; Michihiro Igarashi; Toshiyuki Someya
Journal:  Mol Brain       Date:  2022-07-26       Impact factor: 4.399

5.  Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.

Authors:  Andrew A Bieberich; Tuomo Laitinen; Kaitlyn Maffuid; Raymond O Fatig; Chad D Torrice; David C Morris; Daniel J Crona; Christopher R M Asquith
Journal:  Sci Rep       Date:  2022-07-27       Impact factor: 4.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.